STE stock sentiment todaySTERIS plc

A high-quality defensive compounder currently stalling due to full valuation and cautious sentiment ahead of Q2 earnings.

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for STE. Not financial advice.

The market is currently wrestling with STE's valuation, as headlines pivot between 'fully priced' and 'defensive hold.' Recent underperformance since the last earnings report has created a 'show-me' narrative for the upcoming Q2 release, with specific focus on the ROI of the $600M chemistry acquisition.

• ·Q2 earnings anticipation and potential guidance revisions
• ·Debate over DCF-based overvaluation (approx. 8%)
• ·Scaling of the $600M chemistry/consumables business
• ·Rotation toward peers like Medtronic perceived to have better value

STERIS maintains a robust balance sheet with consistent free cash flow generation. While margins are healthy due to the recurring nature of the sterilization and consumable business, top-line growth is stabilizing into the mid-single digits, making current P/E multiples look stretched relative to growth.

• ·Operating Margin: ~20-22%
• ·Recurring Revenue: ~80% (Services + Consumables)
• ·Debt-to-Equity: Manageable (~0.5x)
• ·Forward P/E: ~24x (High relative to 5-year historical average)

Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.

Mixed conviction — no decisive signal from insiders or the holder base.

• ·Insiders sold a net $957K on the open market in the last 120 days.

Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.

• ·Exposure to hospital CapEx cycles which can be sensitive to interest rates
• ·Integration risks of recent large-scale acquisitions
• ·Regulatory scrutiny over Ethylene Oxide (EtO) emissions
• ·Valuation compression if Q2 organic growth misses consensus

How direct competitors stack up against STE right now.

• HOT
  MDTMedtronic plc

  HOTTER — Trading at a significantly lower forward P/E (~15x vs STE's 24x) with a higher dividend yield and improving pipeline momentum.

  See full analysis →
• NEUTRAL
  TMOThermo Fisher Scientific

  NEUTRAL — Offers superior scale and R&D exposure but faces similar valuation headwinds in a high-rate environment.

  See full analysis →
• HOT
  SYKStryker Corporation

  HOTTER — Delivering stronger organic sales growth (8-10%) and benefiting from a robust rebound in elective procedure volumes.

  See full analysis →

Consensus average of 3 analysts · median 270.00

Source: StockAnalysis.com · updated 2026-08-17

• TradingView
  STERIS Set to Report Q2 Earnings: What's in the Cards for the Stock?
• Yahoo Finance
  STERIS (STE) Stock Looks Fully Priced on Current Cash Flow Expectations
• Trefis
  Should Steris Stock Holders Look At Medtronic Instead?
• Simply Wall St
  STERIS (STE) Stock May Be 8% Overvalued On Current Cash Flow
• Yahoo Finance
  Reasons to Add STE Stock to Your Portfolio Right Now
• Yahoo! Finance Canada
  STERIS plc (Ireland) (STE) Stock Forecasts